Merck KGaA: multiple sclerosis pill shows efficacy, safety
(CercleFinance.com) - Germany's Merck today unveiled new data for Mavenclad, which further characterises the long-term efficacy and safety profile of its multiple sclerosis pill.
According to results from a post-hoc analysis, 75% of patients showed stable or improved disability status five years after treatment.
This data has been shared at the congress of the European Committee for Treatment and Research In Multiple Sclerosis (ECTRIMS), taking place in Stockholm, Sweden.
Mavenclad has been approved in 69 countries, including the US.
Copyright (c) 2019 CercleFinance.com. All rights reserved.